[Skip to Content]
[Skip to Content Landing]
Editorial
March 2014

Genetics of Atopic Dermatitis: Beyond Filaggrin—the Role of Thymic Stromal Lymphopoietin in Disease Persistence

Author Affiliations
  • 1The Institut National de la Santé et de la Recherche Médicale (INSERM), U781, Université Paris Descartes–Sorbonne Paris Cité, Institut Imagine, Paris, France
  • 2Department of Genetics, Necker–Enfants Malades Hospital, Paris, France
 

Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Dermatol. 2014;150(3):248-250. doi:10.1001/jamadermatol.2013.7994

In this issue of JAMA Dermatology, Margolis et al1 report the association of a thymic stromal lymphopoietin (TSLP) variant with disease remission in children with atopic dermatitis (AD), particularly in those carrying filaggrin gene (FLG) mutations. Thymic stromal lymphopoietin, an epithelial cell-derived cytokine, is a master initiator of helper T cell type 2 (TH2) differentiation and allergic manifestations.2 These results suggest that TSLP could be a possible dual factor in AD, capable of modulating the effects of FLG mutations in triggering allergic manifestations. Alternatively, this single-nucleotide polymorphism (SNP) variant could be in linkage disequilibrium, with a causative variant to be identified, localized within or outside TSLP. Functional and expression studies of this TSLP SNP variant will be instrumental to assess its role(s) in the disease.

×